Tarenflurbil

Summary

Tarenflurbil (CHEMBL190083) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including dementia and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 244.26 Da · C15H13FO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL190083
Name	Tarenflurbil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	92337
ChEBI	CHEBI:38666
Molecular formula	C15H13FO2
Molecular weight	244.26
InChIKey	SYTBZMRGLBWNTM-SNVBAGLBSA-N

SMILES: C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O

IUPAC name: (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid

Also known as: E-7869, Flurbiprofen, (r)-, MPC-7869, R-flurbiprofen, Tarenflurbil, Tarenflurbilo, (R)-flurbiprofen, SID11112562, SID11114208, SID520769, SID520770, TARENFLURBIL

Patent coverage: 1,820 distinct patent families (4,903 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,752 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Fructose-bisphosphate aldolase, Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Menin/Histone-lysine N-methyltransferase MLL, Gamma-secretase, Prostaglandin G/H synthase 1, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	6.2	Potency	631	nM	CHEMBL_ACT_4017413
CYP2C19	6.2	AC50	631	nM	CHEMBL_ACT_6048399
Q05769	5.89	IC50	1300	nM	CHEMBL_ACT_12055663
HIF1A	5.7	Potency	1995	nM	CHEMBL_ACT_4129025
HIF1A	5.7	Potency	1995	nM	CHEMBL_ACT_4520847
LMNA	5.5	Potency	3162	nM	CHEMBL_ACT_3656515
CYP2C9	5.1	Potency	7943	nM	CHEMBL_ACT_5041545
CYP2C9	5.1	AC50	7943	nM	CHEMBL_ACT_5999096
CYP2C9	5	Potency	10000	nM	CHEMBL_ACT_5077180
CYP2C9	5	AC50	10000	nM	CHEMBL_ACT_5989069
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6025124

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dementia	3	MONDO:0001627	HP:0000726
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00105547	PHASE3	COMPLETED	Efficacy Study of MPC-7869 to Treat Patients With Alzheimer’s
NCT00322036	PHASE3	TERMINATED	Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer’s
NCT00380276	PHASE3	TERMINATED	Open-Label Treatment With MPC-7869 for Patients With Alzheimer’s Who Previously Participated in an MPC-7869 Protocol
NCT00045123	PHASE2	UNKNOWN	R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
NCT02206854	PHASE1	COMPLETED	Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).